Top 3 formulary access takeaways for pharma
Three items you need to know from "Formulary Fireworks"
The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.